Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{169909,
        author = {Jasmin Rashid Bagwan and Mujeeb Muhamadhusen Shaikh},
        title = {Emodin and Isoproterenol in Cardiac Hypertrophy: An Overview of Their Mechanisms, Potential Treatments, and Future Prospects},
        journal = {International Journal of Innovative Research in Technology},
        year = {2024},
        volume = {11},
        number = {6},
        pages = {2496-2498},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=169909},
        abstract = {An adaptive response to elevated hemodynamic load or neurohormonal stimulation is cardiac hypertrophy. Prolonged hypertrophy, though initially compensatory, can result in maladaptive remodeling and cardiac failure. Characterizing the molecular mechanisms mediating hypertrophic responses is necessary to develop specific therapeutic strategies. Isoproterenol-induced cardiac hypertrophy is an established experimental paradigm mimicking sympathetic over activation seen in several cardiac diseases. Emodine, on the other hand, has been a focus of attention as a compound that possess cardioprotective, antioxidant and anti-inflammatory activities [2–4].. The purpose of this review is to summarize what is currently known about how emodine and isoproterenol interact with cardiac hypertrophy.},
        keywords = {},
        month = {November},
        }